medigraphic.com
ISSN 1561-302X (Print)

2021, Number 4

<< Back Next >>

Rev cubana med 2021; 60 (4)

Comorbidities in patients with psoriatic arthropathy

Casas FN, Torres TVM, Chico CA, Argüelles ZA, Gutiérrez RÁR

Language: Spanish
References: 31
Page: 1-13
PDF size: 331.86 Kb.


ABSTRACT

Introduction: In recent years, various investigations have shown that the presence of comorbidity worsens the prognosis of patients with psoriatic arthritis.
Objective: To determine the comorbidities in patients diagnosed with psoriatic arthritis.
Methods: A descriptive cross-sectional study was conducted in the Rheumatology service of the “Hermanos Ameijeiras” Clinical-Surgical Hospital, which included 111 patients with psoriatic arthritis from January 2016 to February 2018.
Results: The age group most represented was that of 50 to 60 years, female sex (63.1%) and white skin color (77.5%) patients predominated. 50.5% had a psoriatic arthritis evolution time greater than 10 years. 94.5% expressed the peripheral joint pattern and the most frequent joint clinical form was oligoarticular (56.7%). The most frequently identified comorbidities were obesity (80.18%), dyslipidemia (68.46%), arterial hypertension (HBP) (54.95%) and non-alcoholic fatty liver (53.15%). 73.0% had three or more comorbidities. The sex and the time of evolution of the disease and the inflammatory activity did not show significant relationship. The inflammatory activity of the disease was demonstrated in 83.8%.
Conclusions: The presence of associated comorbidities was evidenced in patients with PsA, with obesity, dyslipidemia, hypertension, and non-alcoholic fatty liver occurring more frequently. A high percentage of patients had more than three comorbidities and no significant association was demonstrated between the number of comorbidities and disease variables.


REFERENCES

  1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritisepidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005[acceso: 28/06/2020];64(2):14-7. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766874/

  2. Chandran V, Raychaudhuri Sp. Geoepidemiology and environmental factors ofpsoriasis and psoriatic arthritis. J Autoinmun. 2010[acceso: 28/06/2020];34:314-21. Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S0896841109001590?via%3Dihub

  3. Pérez Alonso T. Psoriasis complicada, diagnóstico y tratamiento. Manual dePrácticas Médicas. Hospital Clínico Quirúrgico “Hermanos Ameijeiras”. 2002. 2daed. La Habana: Ed. 2008; p. 351-3.

  4. Moll J, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973[acceso:28/06/2020];3:5-78. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/0049017273900358?via%3Dihub

  5. Ogdie A, Weiss P. The epidemiology Psoriatic Arthritis. Rheum Dis Clin NorthAm. 2015[acceso: 28/06/2020];41(4):545-68. Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S0889857X15000502?via%3Dihub

  6. Gladman DD, Farewell VT, Wong K. Mortality studies in psoriatic arthritis:Results from a single outpatient center. II. Prognostic indicators for death.Arthritis Rheum. 1997[acceso: 28/06/2020];40:1103-10. Disponible en:https://onlinelibrary.wiley.com/doi/10.1002/1529-0131(199806)41:6%3C1103::AID-ART18%3E3.0.CO;2-N

  7. Feinstein AR. The pre-therapeutic classification of comorbidity in chronicdisease. J Chronic Dis. 1970[acceso: 27/06/2020];23:455-68. Disponible en:https://pubmed.ncbi.nlm.nih.gov/26309916/

  8. Husni ME. Comorbidities in Psoriatic Arthritis. Rheum Dis Clin North Am.2015[acceso: 28/06/2020];41(4):677-98. Disponible en:https://www.sciencedirect.com/science/article/abs/pii/S0889857X15000575?via%3Dihub

  9. Haque N, Lories RJ, De Vlam K. Comorbidities associated with psoriatic arthritiscompared with non-psoriatic spondyloarthritis: a cross-sectional study. JRheumatol.2016[acceso: 28/06/2020];43:376-82. Disponible en:https://www.jrheum.org/content/43/2/376.long

  10. Taylor W. Classification criteria for psoriatic arthritis development of newcriteria from a large international study. Arth Rheum. 2006[acceso:28/06/2020];54:2665-73. Disponible en:https://onlinelibrary.wiley.com/doi/10.1002/art.21972

  11. Ariza-Ariza R, Hernández-Cruz B, Navarro-Sarabia F. La versión española delBASDAI es fiable y se correlaciona con la actividad de la enfermedad en pacientescon espondilitis anquilosante. Rev Esp Reumatol. 2004[acceso:28/06/2020];31:372-77. Disponible en: https://medes.com/publication/13876

  12. Declaración de Helsinki de la Asociación Médica Mundial. Principios éticos paralas investigaciones médicas en seres humanos. Fortaleza, Brasil. AsociaciónMédica Mundial. 2013[acceso: 28/06/2020]. Disponible en:https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-ammprincipios-eticos-para-las-investigaciones-medicas-en-seres-humanos/

  13. Schneeweiss M, Merola JF, Karlson EW, Solomon DH. Rationale and Design ofthe Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). BMCDermatol. 2017[acceso: 28/06/2020];17(1):11. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559864/

  14. Ni C, Chiu M. Psoriasis and comorbidities: links and risks. Clin Cosmet InvestigDermatol. 2014[acceso: 28/06/2020];7:119-32. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000177/

  15. Ponce M, Mendoza R. Características clínico-epidemiológicas de pacientes conpsoriasis en un hospital nacional. Dermatol Perú. 2012[acceso:28/06/2020];22:144-50. Disponible en:https://sisbib.unmsm.edu.pe/bvrevistas/dermatologia/v22_n3/pdf/a02v22n3.pdf

  16. Chanussot C, Arenas R. Psoriasis. Estudio descriptivo y comorbilidades en 114pacientes. Dermatología CMQ. 2015[acceso: 13/03/2020];13(1). Disponible en:https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=57442

  17. Malm AG, Salvesen O, Stoklund RT, Kavanaugh A, Grete AS, Rollef S, et al.Change in cardiovascular risk factors in patients who develop psoriatic arthritis:longitudinal data from the Nord- Trøndelag Health Study (HUNT). RMD Open.2018[acceso: 28/06/2020];4(1):e000630. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856915/

  18. Ranza R, Carneiro S, Qureshi AA, Martins G, Rodrigues JJ, Romti R, et al.Prevalence of psoriatic arthritis in a large cohort of Brazilian patients withpsoriasis. J Rheumatol. 2015[acceso: 28/06/2020];42:829-34. Disponible en:https://www.jrheum.org/content/42/5/829.long

  19. Parisi R, Rutter MK, Lunt M, Young HS, Symmons DPM, Griffiths CEM, et al.Identification and management of psoriasis associated comorbidity (IMPACT)project team. Psoriasis and the risk of major cardiovascular events: Cohort studyusing the clinical practice research datalink. J Investig Dermatol. 2015[acceso:28/06/2020];135:2189-97. Disponible en:https://www.sciencedirect.com/science/article/pii/S0022202X15390266?via%3Dihub

  20. Yim KM, Armstrong AW. Updates on cardiovascular comorbidities associatedwith psoriatic diseases: epidemiology and mechanisms. Rheumatol Int.2017[acceso: 28/06/2020];37(1):97-105. Disponible en:https://link.springer.com/article/10.1007%2Fs00296-016-3487-2

  21. Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016[acceso:28/06/2020];232:633-923. Disponible en:https://link.springer.com/article/10.1007%2Fs00296-016-3487-2

  22. Galíndez E, Carmona L. ¿Se asocia la obesidad en la artritis psoriásica a unamenor respuesta terapéutica y más efectos adversos con el tratamiento de fondo?Reumatol Clín. 2016[acceso: 28/06/2020]; 12(6):307-12. Disponible en:http://dx.doi.org/10.1016/j.reuma.2015.12.005https://www.reumatologiaclinica.org/es- se-asocia-obesidad-artritis-psoriasicaarticulo-S1699258X15002296

  23. Wolk K, Sabat R. Adipokines in psoriasis: an important link between skininflammation and metabolic alterations. Rev Endocr Metab Disord. 2016[acceso:28/06/2020];17:305-1. Disponible en:https://link.springer.com/article/10.1007%2Fs11154-016-9381-0

  24. Zaffarana CA, Schneeberger EE, Gallino JY, Cerda O, Landi M, Citera G.Prevalencia de obesidad en una cohorte de pacientes con artritis psoriásica y factores asociados. Rev Arg Reumatol. 2017[acceso: 28/06/2020];28(2):19-25.Disponible en: http://revistasar.org.ar/revistas/2017/n2/3_articulo_original.pdf

  25. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association betweenpsoriasis and dyslipidaemia: A systematic review. Br J Dermatol. 2013[acceso:28/06/2020];168:486-95. Disponible en:https://onlinelibrary.wiley.com/doi/10.1111/bjd.12101

  26. Peluso R, Casoa F, Tassoa M, Ambrosinob P, Nicola M, Di Minnoc D, et al.Cardiovascular risk markers and major adverse cardiovascular events in psoriaticarthritis patients. Rev Recent Clin Trials. 2018[acceso: 28/06/2020];13:199-209.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691775/

  27. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at ahigher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol.2015[acceso: 28/06/2020];40(7):722-7. Disponible en:https://onlinelibrary.wiley.com/doi/10.1111/ced.12672

  28. Ogdie A, Grewa SK, Noe Megan H, Shin D, Takeshita J, Chiesa Fuxench Z, etal. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, andrheumatoid arthritis: a population-based study. J Invest Dermatol. 2018[acceso:28/06/2020];138(4):760-7. Disponible en:https://www.sciencedirect.com/science/article/pii/S0022202X1733097X?via%3Dihub

  29. Yim KM, Armstrong AW. Updates on cardiovascular co-morbidities associatedwith psoriatic diseases: epidemiology and mechanisms. Rheumatol Int.2017[acceso: 28/06/2020];37:97-105. Disponible en:https://link.springer.com/article/10.1007%2Fs00296-016-3487-2

  30. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, van Voorhees AS, et al.Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017[acceso:28/06/2020];76:377-90. Disponible en:https://www.sciencedirect.com/science/article/pii/S0190962216306260?via%3Dihub

  31. Husted J, Thavaneswaran A, Chandran V, Gladman D. Incremental effects ofcomorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol.2013[acceso: 28/06/2020];40(8):1349-56. Disponible en:https://www.jrheum.org/content/40/8/1349.long




2020     |     www.medigraphic.com